{
    "nctId": "NCT03787303",
    "briefTitle": "Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma",
    "officialTitle": "A Single Arm Phase II Pilot Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer, Thyroid Dysfunction",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Number of Participants With Progression-free Survival at 12 Months Based Upon Clinical and Radiological Assessments Completed as Part of Routine Care",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age greater than or equal to 18\n* Male or female with diagnosis of metastatic breast carcinoma and documented history of hypothyroidism .\n* TSH level within normal range at baseline\n* Life expectancy estimated \\> 3 months\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Life expectancy estimated to be less than 3 months\n* Is currently pregnant or intends to become pregnant during the duration of the study\n* Active angina, New York Heart Association (NYHA) advanced \\[Class III/IV\\] congestive heart failure, or uncontrolled cardiac arrhythmia within 6 months of enrollment\n* History of thyrotoxicosis\n* History of adrenal insufficiency\n* Hypersensitivity to any active or extraneous constituents in Triiodothyronine (T3)/liothyronine sodium",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}